tbuckley/cabot-search huggingface dataset:
AB1110 What can google trends can tell us about a disease? big data trends analysis in systemic lupus erythematosus
Authors: S Sciascia, M Radin
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> "<i>Infodemiology</i>" and "<i>infoveillance</i>" are two recent terms created to describe a new developing approach for public health, based on Big Data monitoring and data mining, applicable to provide new insights into unmet needs, such as the epidemiology of an uncommon disease like Systemic Lupus Erythematosus (SLE)[1]. Analysing how people (including patients, researchers, physicians) search and navigate the Internet for health-related information, as well as how they communicate and share this information, can provide valuable insights into health-related behaviour of populations. <h3>Objectives</h3> In this study we aimed to investigate trends of Internet search volumes linked to SLE, on-going clinical trials and research developments associated to the disease, using Big Data monitoring and data mining. We also aimed to analyse peak-related information to investigate knowledge translation of novel therapies for SLE and the influence of media on health-related information seeking. <h3>Methods</h3> We performed a longitudinal analysis based on the large amount of data generated by Google Trends, scientific search tools (SCOPUS, Medline/Pubmed/ClinicalTrails.gov) considering "SLE", and "lupus" in a 5-year web-based research. <h3>Results</h3> We observed an overall higher distribution of search volumes from Google Trends in United States, South America, Canada, South Africa, Australia and Europe (mainly Italy, United Kingdom, Spain, France, Germany), showing a geographically heterogeneity in insight into health-related behaviour of the different populations towards SLE. Data from Medline/Pubmed, SCOPUS and ClinicalTrials.gov were also analysed in order to monitor public health relevant publications and on-going trials. When comparing these results to the distribution of search volumes of Google Trends, we observed an overall similar distribution of Big Data for United States and Europe, while South America, Canada, Australia and South Africa were less represented. We observed a misbalance between search volumes for Google Trends compared to Medline/Pubmed, SCOPUS and ClinicalTrials.gov in some areas, suggesting a recent and expanding interest on SLE-related health issues in some countries. <h3>Conclusions</h3> We observed in some countries a misbalance between the search volumes generated by Google Trends and those analyzed through scientific search tools. This new approach, merging togheter informatics and epidemiology, is able to investigate health information seeking. In the near future it might give an estimate of the health-related demand and even of the health-related behaviour of patients with SLE. <h3>References</h3> Eysenbach G. Infodemiology and infoveillance: framework for an emerging set of public health informatics methods to analyze search, communication and publication behavior on the Internet. J Med Internet Res 2009;11:e11. doi:10.2196/jmir.1157. <h3>Disclosure of Interest</h3> None declared
Female genital mutilation - a form of child abuse. by Patricia Schroeder
Authors: Patricia Schroeder
Journal: New England Journal of Medicine (1994)

tag=1 data=Female genital mutilation - a form of child abuse. by Patricia Schroeder

tag=2 data=Schroeder, Patricia

tag=3 data=The New England Journal of Medicine,

tag=4 data=331

tag=5 data=11

tag=6 data=15 September 1994

tag=7 data=739-740.

tag=8 data=WOMEN

tag=10 data=Even in countries where female genital mutilation is an age-old tradition, the belief that it should be eliminated is growing. Provided by MICAH.

tag=11 data=1995/1/1

tag=12 data=95/0029

tag=13 data=CAB
Diabetes Research and Care Through the Ages
Authors: Bernard Zinman, Jay S. Skyler, Matthew C. Riddle, Ele Ferrannini
Journal: Diabetes Care (2017)

As has been well established, the Diabetes Care journal's most visible signature event is the Diabetes Care Symposium held each year during the American Diabetes Association's Scientific Sessions. Held this past year on 10 June 2017 in San Diego, California, at the 77th Scientific Sessions, this event has become one of the most attended sessions during the Scientific Sessions. Each year, in order to continue to have the symposium generate interest, we revise the format and content of this event. For this past year, our 6th annual symposium, I felt it was time to provide a comprehensive overview of our efforts in diabetes care to determine, first and foremost, how we arrived at our current state of management. I also felt the narrative needed to include the current status of management, especially with a focus toward cardiovascular disease, and finally, we wanted to ask what the future holds. Toward this goal, I asked four of the most noted experts in the world to provide their opinion on this topic. The symposium started with a very thoughtful presentation by Dr. Jay Skyler entitled "A Look Back as to How We Got Here." That was followed by two lectures on current concepts by Dr. Bernard Zinman entitled "Current Treatment Paradigms Today-How Well Are We Doing?" and by Dr. Matthew Riddle entitled "Evolving Concepts and Future Directions for Cardiovascular Outcomes Trials." The final lecture for the symposium was delivered by Dr. Ele Ferrannini and was entitled "What Does the Future Hold?" As always, a well-attended and well-received symposium is now the norm for our signature event and our efforts were rewarded by the enthusiasm of the attendees. This narrative summarizes the lectures held at the symposium.-William T. CefaluChief Scientific, Medical & Mission Officer, American Diabetes Association.
Daratumumab, a CD38 mab, for the treatment of relapsed/refractory multiple myeloma patients: Preliminary efficacy data from a multicenter phase I/II study.
Authors: Torben Plesner, Henk M Lokhorst, Peter Gimsing, Hareth Nahi, Steen Lisby, Paul Gerard Guy Richardson
Journal: Journal of Clinical Oncology (2012)

8019 Background: Daratumumab (HuMax-CD38) is a human CD38 monoclonal antibody with broad-spectrum killing activity; it effectively kills CD38-expressing tumor cells via antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and apoptosis. From an ongoing first-in-human (FIH) dose-escalation study (ClinicalTrials.gov CT00574288), it has been shown that daratumumab has an acceptable safety profile (Gimsing: ASH 2011 abstract 1873). The objectives of this FIH study are to establish the safety profile and MTD. In addition efficacy is evaluated. Methods: Pts ≥18 years and previously diagnosed with MM requiring systemic therapy and considered relapsed or refractory (RR) to at least two different prior lines of therapy and not eligible for salvage ASCT were enrolled. The design of this study encompasses an accelerated dose-escalation based on a classical 3+3 design. Daratumumab is administrated over a 9 wk period encompassing 2 pre-doses and 7 full-doses. The doses range from 0.005 mg/kg to 24 mg/kg. The decision to dose escalate is based on recommendation by an external Independent Data Monitoring Committee. Evaluation of efficacy data was according to Rajkumar (Blood 2011;117:4691-5) . The results presented in this abstract are based on preliminary data analyzed before database lock. Results: Data from 23 pts including the 4 mg/kg group are collected. Preliminary efficacy evaluation is based on best paraprotein response as reflected by change in serum and/or urine M-component. For groups ≤ 1 mg/kg, 3/17 pts achieved a reduction in serum M-component (12%, 14%, 19%), in the 2 mg/kg group, 1/3 pts had a reduction in urine M-component (55%), and in the 4 mg/kg group, 3/3 pts had a reduction in the serum M-component of 49%, 55, and 64%, respectively. In the 4 mg/kg group a marked reduction in the percentage of plasma cells in the bone marrow was seen in all pts (80%, 89%, and 97%). The toxicity was manageable. Conclusions: Daratumumab treatment resulted in reductions in M-component and bone marrow plasma cells in pts with RR MM. Toxicity has been manageable. Additional data will be presented at the meeting.
Abstract #999: A prospective study of telomere length and risk of lung cancer
Authors: Min Shen, Richard Cawthon, Stephanie Weinstein, Jarmo Virtamo, Unhee Lim, Dean Hosgood, Demetrius Albanes, Nathaniel Rothman, Qing Lan
Journal: Cancer Research (2009)

Telomere length plays an important role in chromosomal stability and tumorigenesis. We hypothesized that telomere length in peripheral white blood cell DNA of healthy male smokers may be a predictor of developing lung cancer. Using a new method, monochrome multiplex quantitative PCR, which eliminates the pipetting variation between wells, we compared relative telomere length in peripheral white blood cell DNA in 229 incident male lung cancer cases and 229 matched controls within the prospective Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Cohort Study of male smokers. Median (10 th , 90 th  percentile) telomere length was 1.13 (0.86, 1.45) in cases and 1.08 (0.85, 1.38) in controls (P = 0.038). Telomere length was inversely associated with age (Spearman correlation  r  = -0.09, P = 0.18) and pack-year of smoking (Spearman correlation  r  = -0.16, P = 0.02) among controls. Compared to subjects with shorter telomere length (\#8804; median telomere length), subjects with longer telomere length (> median telomere length) had 1.6-fold (95% CI, 1.07-2.39) increased risk of lung cancer. There was a significant dose-response relationship between quartiles of telomere length and risk of lung cancer (odds ratios by quartile: 1.00, 1.00 (0.56-1.79), 1.64 (0.96-2.82), and 1.55 (0.87-2.79); P  trend  = 0.04). In addition, stratified analysis showed that longer telomere length was associated with increased risk of lung cancer among heavy smokers with > 33 pack-years smoking (OR, 2.50; 95% CI, 1.51-4.13) but not among light smokers with \#8804; 33 pack-years smoking (OR, 0.90; 95% CI, 0.50-1.61) (P  interaction  = 0.01). Our results suggest that longer telomere length may be associated with future risk of lung cancer among male smokers, especially among heavy smokers.   Citation Information:  In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 999.
Breast cancer in male veterans: A retrospective chart review.
Authors: Anita Aggarwal, Min-Ling L Liu, Nihar Kiritkumar Patel, Rebecca Evangelista, Steven Krasnow
Journal: Journal of Clinical Oncology (2013)

e12531 Background: Male breast cancer (BCA) is rare and makes up &lt; 1% of all of breast cancer cases. Treatment is mainly based on what is known from female BCA and survival is similar between genders. Objectives: To investigate the clinicopathologic characteristics of BCA and overall survival in male veterans. Methods: Medical records of male patients diagnosed with breast cancer at the Veterans Affairs Medical Centers of Washington DC, Baltimore and Martinsburg from 1992-2012 were reviewed after Institutional Review Board approval. Results: From 1995-2012, 51 male patients with BCA were identified from cancer registry. 29/51(57%) were African American (AA), 41% Caucasian (WM), and 2% other race. Median age was 70 years (44-86years). Palpable mass was presenting symptom in 41/51(80%) and 8(16%) had gynecomastia or bloody nipple discharge. Family history of breast cancer was positive in 11 patients without mention of BRCA genes except pt #24 who was BRCA2+. 3 patients were exposed to Agent Orange. ER/PR was positive in 36(71%), ER+/PR- in 1(2%), ER+/PR+/HER2+ in 2(4%), ER-/PR-/HER- in 2(4%). 41% &amp; 57% had right and left BCA, respectively. 40 (80%) underwent mastectomy. 18(36%) had lymph node involvement (1-13 LN). 90% had invasive ductal carcinoma (IDC), 8% DCIS, and 2% sarcoma. Cancer in 26% was stage I, 38% stage II, 18% stage III and 8% stage IV. 12(24%) received combination chemotherapy. 33(66%) were given tamoxifen. 4(8%) patients had relapsed/recurrent disease in 1-5 years of their diagnosis and died within 2-12 years after the relapse. At median follow up of 174m (4m-19years), 28(56%) patients died (cause of death not known in all), 21(42%) alive and 3(6%) lost to follow up. Conclusions: Median age at diagnosis of BCA seems to be higher in males (70 years) as compared to historical female age (60 years). IDC is the main pathology and 73% tumors were ER +. Survival rate is approximately 40% at &gt;10years of follow up. Survival by stage revealed no difference.
Indoor microbiome and asthma: a case-control study within ECRHS
Authors: J. Pekkanen, M. Valkonen, M. Taubel, H. Leppanen, P. Karkkainen, H. Rintala, J. Zock, L. Casas, C. Tischer, N. Probst-Hensch, B. Forsberg, M. Holm, Christer Jahnson, I Pin, T. Gislason, D. Jarvis, J. Heinrich, A. Hyvarinen
Journal: Allergy (2017)
A randomized phase III trial of docetaxel plus cisplatin or paclitaxel plus carboplatin compared with doxorubicin plus cisplatin as adjuvant chemotherapy for endometrial cancer at high risk of recurrence: Japanese Gynecologic Oncology Group study (JGOG2043).
Authors: Hiroyuki Nomura, Daisuke Aoki, Hirofumi Michimae, Mika Mizuno, Hidekatsu Nakai, Masahide Arai, Motoi Sasagawa, Kimio Ushijima, Toru Sugiyama, Motoaki Saito, Hideki Tokunaga, Kohei Omatsu, Toru Nakanishi, Yoh Watanabe, Toshiaki Saito, Nobuo Yaegashi
Journal: Journal of Clinical Oncology (2017)

5503 Background: The superiority of chemotherapy regimens employing a taxane plus a platinum agent over standard therapy with doxorubicin plus cisplatin (AP) was recently demonstrated for advanced or recurrent endometrial cancer. This multicenter phase III trial evaluated the clinical benefit of taxane plus platinum agent regimens as adjuvant chemotherapy compared with AP for endometrial cancer patients at high risk of recurrence after surgery. Methods: Endometrial cancer patients having a high risk of recurrence and postoperative residual disease &lt; 2 cm were randomly assigned (1:1:1) with stratification by FIGO stage and histologic grade to receive 6 cycles of doxorubicin (60 mg/m 2 ) plus cisplatin (50 mg/m 2 ) on day 1 (AP), docetaxel (70 mg/m 2 ) plus cisplatin (60 mg/m 2 ) on day 1 (DP) or paclitaxel (180 mg/m 2 ) plus carboplatin (AUC 6.0 mg/mL x minute) on day 1 (TC) every 3 weeks as adjuvant chemotherapy. The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall survival (OS), adverse events, and tolerability. Results: From November 2006 to January 2011, 788 patients were enrolled from 118 institutions in Japan and were eligible for evaluation. The proportion of patients receiving 6 cycles was 80% for AP, 83% for DP, and 76% for TC, and tolerability of the regimens showed no significant difference. After a median follow-up period of 7.0 years, there was no statistical difference of PFS (P=0.1246) or OS (P=0.6734) among the 3 groups. The 5-year PFS rate was 74.9% for AP, 80.9% for DP, and 74.7% for TC, while the 5-year OS rates were 84.3%, 89.3%, and 88.4%, respectively. Conclusions: There was no significant difference of survival among patients receiving AP, DP, or TC as adjuvant chemotherapy for endometrial cancer. Since each regimen showed adequate tolerability, taxane plus platinum agent regimens may be a reasonable alternative to AP. Clinical trial information: UMIN000000522.
AB1157 Prevalence of musculoskeletal disorders among garment industry workers in bangladesh
Authors: SA Haq, N Shazzad, S Ahmed, AZ Al-Qadir, A Shahin
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Garments industry is flourishing in many developing countries. Attention is often not paid to ergonomics. It is plausible that the prevalence of musculoskeletal (MSK) pain may be high among garments workers. <h3>Objectives</h3> To estimate the prevalence of symptoms and disorders (MSD) among garment workers in Bangladesh. <h3>Methods</h3> This cross sectional study was carried out among 350 workers in two garment factories by face-to-face interview. The COPCORD (Community Oriented Program for Control of Rheumatic Disorders) methodology was adopted for the survey.The workers were classified into cutting, sewing, finishing and quality control operators. Trained interviewers identified subjects with musculoskeletal pain. Trained internists and rheumatologists examined the positive respondents. <h3>Results</h3> The point prevalence of musculoskeletal pain was 61.71%. The parts commonly affected during the preceding 7 days of interview in the whole group were shoulder (17.9%), lower back (15.2%), neck (13.8%) and knee (10.8%). The cutting operators suffered more from back (15.4%), neck (15.4%) and lower limb (11.5%); sewing operators from lower limb (12.4%), back (8.5%) and upper limb (7.7%); finishing operators from lower limb (50%) and quality control group from back pain (50%). Multiple regional pains were more frequent (n=155) among all operators.The sewing and cutting operators suffered from multiple regional pains more than other operators.The prevalence of Rheumatoid arthritis (RA) 0.9%, spondyloarthropathy (SpA) 1.42%, undifferentiated arthritis (UA) 1.1%, nonspecific low back pain (NSLBP) 4.6%, soft tissue rheumatism (STR) 3.7%, osteoarthritis (OA) 0.9% and lumbarspondylosis 1.1%.Nonspecific pain was the commonest condition (63.71%). <h3>Conclusions</h3> Rheumatic disorders are common causes of morbidity, disability, and work loss among the garment workers of Bangladesh where male and female workers are almost equally affected. Multiple regional involvementsare common in this occupational group. Mechanical disorders are the commonest. <h3>Disclosure of Interest</h3> None declared
FRI0594 A case of mosaicism in TNF associated periodic syndrome (TRAPS)
Authors: A Kontzias, C Calabrese, Y-W Cheng
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Tumor necrosis factor receptor (TNFR)–associated periodic syndrome (TRAPS) is an autosomal-dominant disease caused by gain-of-function mutations in the TNFRSF1A gene, which encodes the 55-kd TNFR type I (TNFRI) protein. Mosaicism has been recently idenitfied in a single patient.<sup>1</sup> A 60 year old male presented with a 6 year history of intermittent fever as high as 103.5, lasting 3–4 weeks with associated peritoneal symptoms, arthralgias, myalgias, lymphadenopathy, bilateral episcleritis, erythematous rash in his torso. Prednisone up to 60 mg daily only partially alleviated his symptoms and colchicine was ineffective. <h3>Objectives</h3> To explore the role of mosaicism in a patient with adult onset TRAPS phenotype. <h3>Methods</h3> DNA was extracted from the patient9s whole blood, saliva and hair root. The TNFRSF1A gene was analyzed by Sanger sequencing in all tissues, and next-generation sequencing in whole blood. In silico molecular modeling was performed to predict the structural and functional consequences of the tumor necrosis factor receptor (TNFR) type I protein mutation. <h3>Results</h3> Sanger sequencing and next-generation sequencing methods revealed differential tissue presence of a misense mutation at c.265 T&gt;C p.Phe89Leu (F89L) Chr12(GRCh37):g.6442960A&gt;G ex3 rs104895245. The mutant allele was present in whole blood and buccal mucosa and absent in hair root, supporting the presence of somatic TNFRSF1A mosaicism. In silico prediction modeling with SIFT and PolyPhen2 suggested that this mutation led to numerous structural rearrangements which resulted in changes in the protein surface profile. The patient had a complete response to treatment with canakinumab an interleukin-1 beta blocker, with resolution of symptoms and normalization of acute-phase protein levels. <h3>Conclusions</h3> This is the second reported case of TNFRSF1A mosaicism in a patient with TRAPS, which was attributable to a de novo mosaic missense mutation in the TNFRSF1A gene. (c.265 T&gt;C) p.Phe89Leu (F89L) The clinical picture in this patient, including the complete response to IL-1 blockade, was typical of that found in TRAPS. This case suggests that adult onset TRAPS phenocopies may be attributed to somatic (or postzygotic) mutations. <h3>References</h3> Rowczenio et al Association of Tumor Necrosis Factor Receptor–Associated Periodic Syndrome With Gonosomal Mosaicism of a Novel 24-Nucleotide TNFRSF1A Deletion ARTHRITIS &amp; RHEUMATOLOGY, Vol. 68, No. 8, August 2016, pp 2044–2049. <h3>Disclosure of Interest</h3> None declared
THU0699 Characterizing and validating the phenotype of knee pain: a latent class analysis
Authors: F Pan, J Tian, D Aitken, F Cicuttini, C Ding, G Jones
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Pain in osteoarthritis (OA) is very common and often involves multiple joints. It is multifactorial and individualised with multiple factors involved in the genesis and pain experience, such as structural pathology, psychological factors and pain coping strategies. Thus it may be possible to group people together based on specific factors which are linked to experiencing pain. <h3>Objectives</h3> To identify and validate the phenotype of knee pain over 10.7 years. <h3>Methods</h3> 1099 participants (mean age 63 years; range 51–81 years) from the population-based Tasmanian Older Adult Cohort study were recruited at baseline. 875, 768 and 563 participants attended years 2.6, 5.1 and 10.7 follow-up, respectively. Demographic, psychological, lifestyle and comorbidities data were obtained at baseline. T1-weighted or T2-weighted fat saturated MRI of the right knee was performed to measure knee structural pathology–cartilage defects, bone marrow lesions (BMLs) and effusion-synovitis at baseline. Knee pain was assessed using Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at each time-point. Presence of pain (yes/no) at the neck, back, hands, shoulders, hips, knees and feet was also assessed by questionnaire at each time-point. Latent class analysis, which can identify unmeasured class membership among participants using observed variables, was used to differentiate "pain phenotypes" considering sex, body mass index (BMI), emotional problems, comorbidities, number of painful sites and knee structural damage on MRI. <h3>Results</h3> Three pain phenotypes were identified: Class 1: high levels of emotional problems and low levels of structural damage (24%); Class 2: high levels of structural damage and low levels of emotional problems (20%); Class 3: relatively low levels of emotional problems and low levels of structural damage (56%). People within Class 1 were more likely to be female, had greater BMI, lower education level, more comorbidities, more severe knee pain and more painful sites as compared to Class 2 and Class 3. Furthermore, WOMAC pain scores and number of painful sites were consistently greater at baseline, 2.6, 5.1 and 10.7 years in Class 1 than Class 2 and Class 3 (all P&lt;0.05). <h3>Conclusions</h3> Psychological and structural factors interact with each other to influence pain perception. <h3>Disclosure of Interest</h3> None declared